US · Healthcare · Biotechnology
EPS came in at -1.02 against a street estimate of -0.22 — a miss of 363.6%.
Analysts rate Nuvectis Pharma Inc a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $35.40.
| Fund | Stake |
|---|---|
| TANG CAPITAL MANAGEMENT LLC | 4.80% |
| BlackRock Inc | 3.10% |
| Perceptive Advisors LLC | 3.10% |
| Soleus Capital Management, L.P. | 3.10% |
| Vanguard Capital Management, LLC | 2.70% |
| Iridian Asset Management LLC | 2.41% |
| Geode Capital Management, LLC | 1.34% |
| Sphera Funds Management Ltd. | 1.19% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Nuvectis Pharma is a clinical-stage biopharmaceutical company developing precision medicines for complement-related conditions and | 2026-11-04 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Cash and cash equivalents were $140.7 million as of September 30, 2026, versus $31.6 million as of December 31, 2025. • Third-qua | 2026-11-04 |
| Company announcement · Q3 2026 NUVECTIS PHARMA, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Company established a new "At the Market" (ATM) offering program on August 21, 2026 • $2 | 2026-08-21 |
| Quarterly report · Q2 2026 NUVECTIS PHARMA, INC. – Q2 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Cash position (June 30, 2026): $22.2 million • Accumulated deficit: $112.8 mill | 2026-08-04 |
| Results announced · Q3 2026 NUVECTIS PHARMA Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash and cash equivalents: $22.2 million as of June 30, 2026 (down from $31.6 m | 2026-08-04 |
| Material agreement · Q2 2026 NUVECTIS PHARMA, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Stock offering size: 5,000,000 shares at $20.00 per share • Additional shares option: Un | 2026-06-30 |
| Company announcement · Q2 2026 NUVECTIS PHARMA, INC. (NVCT) - FORM 8-K SUMMARY HEADLINE NUMBERS • Company has reduced available sales capacity under its Sales Agreement from an un | 2026-06-29 |
| Quarterly report · Q1 2026 NUVECTIS PHARMA, INC. — Q1 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Cash and cash equivalents (March 31, 2026): $25,130 thousand ($25.1 million) • | 2026-05-05 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Nuvectis Pharma Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.